Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer Res. 2011 Jul 11;71(17):5904–5914. doi: 10.1158/0008-5472.CAN-10-4173

Figure 6.

Figure 6

Specificity of GANT61 for targeting Gli1 and Gli2 in human colon cancer cells. Binding between Gli1 or Gli2 and the promoter regions of HIP1 and BCL-2 but not FAS, was inhibited in GANT61-treated cells. HT29 cells treated with GANT61 (20 µM) for 24 hr (A) or 1 hr (C) were employed for chromatin immunoprecipitation (ChIP) analysis using antibodies specific for Gli1, Gli2, IgG (negative control), or histone H3 (positive control, used for normalization). Subsequent qPCR used primers that flanked the promoter regions of the Gli target genes, HIP1 and BCL-2 or FAS (negative control and not a direct Gli target). B. GANT61 treatment (20 µM; 24 hr) of HT29 cells demonstrated specific decreased reporter activity of a Gli-luciferase reporter. In contrast, exposure to GANT61 did not affect luciferase activity in HT29 cells transfected with p65 (NFκB)- or AP1- luciferase reporters. D. GANT61 treatment (20 µM; 1hr) of HT29 cells inhibits the transcriptional regulation of BCL-2.